Kaiser Permanente’s national co-leader for COVID-19 vaccination tells Kaiser Health News that an online registration tool is coming soon.
Kaiser Permanente's national infectious disease leader says that the organization is working with the state and the federal government to inform them on COVID-19 vaccine supply needs.
Our Vaccine Study Center will lead an effort in searching medical records for serious reactions among patients who receive the vaccine.
In a New York Times op-ed, two emergency medicine doctors call for a public health campaign with trusted voices from the Black communities.
The development of a COVID-19 vaccine is being celebrated by frontline physicians, clinicians, nurses, and medical staff across the country.
Kaiser Permanente's national infectious disease leader underscores the safety of recently approved COVID-19 vaccines and the importance of avoiding holiday travel.
National infectious disease leader Stephen Parodi, MD, stresses the importance of avoiding holiday travel, wearing a mask, and practicing social distancing to prevent the spread of COVID-19.
In addition to communicating the safety of the Pfizer-BioNTech COVID-19 vaccine, public health messages must continue to emphasize the ongoing need for precautions to prevent the spread of COVID-19.
Kaiser Permanente’s national infectious disease leader expressed confidence in the safety and efficacy of the vaccine, given the organization’s participation in Pfizer-BioNTech COVID-19 vaccine trials.
The late-stage clinical trial will test the vaccine in 1,400 adults at 4 sites in California and Oregon.